Cystic Fibrosis Treatment Products

CSHCN Services Program

HHSC requires prior authorization for claims for Cayston, Kalydeco, Pulmozyme, and inhaled tobramycin. Prescribing providers complete and submit the Cystic Fibrosis Treatment Products Authorization Request (HHS Form 1143).

Pharmacy providers can submit an eligibility verification transaction to find a client's most current period of approval for Tobramycin. Refer to the Eligibility Verification (E1) Transaction for specific transaction, segment, field requirements, and response messages.